PharmAla files U.S. registration statement with the SEC

PharmAla Biotech Holdings Inc. (MDMA) — PharmAla Biotech filed a registration statement with the U.S.

Securities and Exchange Commission detailing a securities offering, part of a series of capital-markets moves that included an earlier base shelf prospectus and a Radium Capital loan facility against Australian R&D tax incentives. The filings aim to give the MDMA supplier financing flexibility as it scales commercial production.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.